News

TURANDOT Revisits Bevacizumab Partners in Metastatic Breast Cancer

Publish date: October 17, 2012

 

AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS

Roche sponsored the TURANDOT trial. Dr. Zielinski disclosed receiving honoraria from the company. Dr. Javier Cortes has received honoraria from Roche.

Pages

Recommended Reading

FDA Approves Ultrasound Screening of Dense Breasts
MDedge Hematology and Oncology
Everolimus Reduces Breast Cancer Treatment Effects in Bone
MDedge Hematology and Oncology
California Enacts Breast Density Notification Law
MDedge Hematology and Oncology
The Cure Is Here, Once Again: Walking the Tightrope Between Hype and Hope
MDedge Hematology and Oncology
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
MDedge Hematology and Oncology
EMILIA Confirms T-DM1 Overall Survival Advantage
MDedge Hematology and Oncology
Another Study Finds No Glargine, Breast Cancer Link
MDedge Hematology and Oncology
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
MDedge Hematology and Oncology
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
MDedge Hematology and Oncology
Baseline Factors Trump Response to Therapy in Mastectomy Decisions
MDedge Hematology and Oncology